Meiji Seika outlines plans for new fiscal year

29 April 2009

Japan's Meiji Seika Kaisha is to  launch two new products in the second half of this fiscal year and increase its sales team by 20%,  according to the Nikkei Weekly. The Japanese financial newspaper claims  Meiji will double sales-force hiring from the previous fiscal year,  which ended in March, to a total of 800. During the period, the firm  will release one antidepressant, whilst granting sales rights to its  mainstay antibiotics to a Russian firm. Lastly, the Nikkei says Meiji  will divert its focus from Asia to emerging markets such as eastern  Europe and the Middle East.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight